Endoscopic Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD) (Transoral Incisionless Fundoplication)
Customize your policy alerts
Sign up for all moda_health_plan_inc policy alerts
Know when moda_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coding, and coverage stance for endoscopic and related minimally invasive procedures to treat GERD for Moda Health Plan members and specifies which procedures are considered medically necessary versus experimental/investigational.
No material clinical or coverage changes in this revision.
Coverage Criteria for Endoscopic GERD Procedures
Transoral Incisionless Fundoplication (TIF) Medical Necessity
Covered when ALL of the following are met:
Age requirement per policy
Exclusions for TIF
- Exclusion: Hiatal hernia greater than 2 cm (hiatal hernia allowed only if 2 cm or less).
- Exclusion: Esophagitis Los Angeles grade C or D.
- Exclusion: Barrett's esophagus.
- Exclusion: Achalasia.
- Exclusion: Esophageal ulcer.
- Exclusion: Esophageal motility disorder.
- Exclusion: Altered esophageal anatomy preventing insertion of the device.
Experimental / Investigational
All other endoscopic procedures for GERD:
Procedures considered experimental and investigational include, but are not limited to, the following devices and techniques: Angelchik anti-reflux prosthesis; EndoCinch™ or Bard Endoscopic Suturing System (BESS); Apollo OverStitch endoscopic suturing system; Enteryx; LINX Reflux Management System (laparoscopic or open); StomaphyX; Full-Thickness Plicator™; Durasphere; Gatekeeper™ Reflux Repair System; Plexiglas or polymethylmethacrylate implantation; Endoscopic Plicator System; Stretta™ System; Syntheon ARD Plicator; and electrical stimulation of the lower esophageal sphincter (EndoStim).
Coverage for Medicare beneficiaries must comply with applicable National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). Where such CMS determinations exist they govern Medicare coverage and may restrict plan coverage; references and current determinations are available through the CMS Medicare Coverage Database. Additional indications may be covered at the discretion of the health plan.
Endoscopic procedures for GERD that are listed as experimental and investigational in this policy are considered not medically necessary due to insufficient published scientific evidence demonstrating long‑term safety and effectiveness. Requests for these procedures may be denied on that basis.
Coding and Diagnosis Codes
| 43201 | Esophagoscopy, rigid or flexible; with directed submucosal injection(s), any substance. |
| 43236 | Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with directed submucosal injection(s), any substance. |
| 43257 | Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease. |
| 43499 | Unlisted procedure, esophagus |
| K21 | Gastro-esophageal reflux disease |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K21 | Gastro-esophageal reflux disease |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| No codes listed |
Provider Responsibilities and Prior Authorization
Comply with CMS NCDs/LCDs and Medicare Benefit Policy Manual
When applicable, providers must follow CMS guidance: compliance with National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and the Medicare Benefit Policy Manual is required; these determinations govern Medicare coverage.
- CMS resources: Medicare Benefit Policy Manual (Pub.100-2), Chapter 15, §50 and the CMS Coverage Database.
- Additional indications may be covered at the plan’s discretion.
Conservative therapy required before TIF
Members must have failed initial management (lifestyle/OTC) and have a history of daily proton pump inhibitor (PPI) therapy for greater than 6 months before TIF will be considered.
- Failure of initial therapy (lifestyle modifications/OTC) precedes PPI use.
- Documented daily PPI therapy duration: > 6 months.
Reference Medicare LCD/NCD guidance for Medicare patients
Follow applicable Medicare LCD guidance when requesting coverage for Medicare members; ensure prior authorization and documentation align with any LCD/NCD language that applies.
- Where NCDs/LCDs exist they govern Medicare coverage and may restrict coverage.
- Link to CMS Coverage Database provided in policy.
Prior authorization documentation required
Submit provider records of the physical exam and symptoms, prior treatments attempted, and prior medical history and surgeries/procedures related to GERD with the prior authorization request.
- Include physical exam findings and symptom history.
- List prior treatments attempted and pertinent surgical history related to GERD.
Use listed ICD-10 diagnosis codes on claims
Use the listed ICD-10 diagnosis codes when submitting claims for endoscopic GERD procedures: K21 (Gastro-esophageal reflux disease) or K21.9 (Gastro-esophageal reflux disease without esophagitis).
- Acceptable diagnosis codes: K21, K21.9.
Non‑TIF endoscopic GERD procedures are experimental/investigational
Requests for endoscopic procedures for GERD other than transoral incisionless fundoplication (TIF) are considered experimental and investigational and may be denied.
- Procedures considered experimental/investigational include (but are not limited to): Stretta System, EndoCinch, Enteryx, LINX (lap/open), StomaphyX, Full-Thickness Plicator, and others listed in the exclusions.
Noncompliance with Medicare coverage guidance may affect decisions
Failure to comply with applicable NCDs, LCDs, or Medicare Benefit Policy Manual guidance may affect coverage decisions for Medicare beneficiaries.
- NCDs/LCDs govern Medicare coverage where they exist and may restrict coverage.
- Ensure prior authorization and submitted documentation align with Medicare policies.
Background and Rationale
Gastroesophageal reflux disease (GERD) results from failure of the lower esophageal sphincter allowing reflux of gastric contents into the esophagus, producing symptoms such as heartburn, cough, and dysphagia. Initial management includes lifestyle modification and acid suppression with proton pump inhibitors; for refractory disease, laparoscopic fundoplication is the surgical standard, while endoscopic approaches such as transoral incisionless fundoplication (TIF) are less invasive alternatives for selected patients.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.